Original Article

Open Access

SNIPER(TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib

Nobumichi Ohoka

Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan

Search for more papers by this author

Katsunori Nagai,

Katsunori Nagai

Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd., Fujisawa, Kanagawa, Japan

Search for more papers by this author

Norihito Shibata,

Norihito Shibata

Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan

Search for more papers by this author

Takayuki Hattori,

Takayuki Hattori

Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan

Search for more papers by this author

Hiroshi Nara,

Hiroshi Nara

Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd., Fujisawa, Kanagawa, Japan

Search for more papers by this author

Nobuo Cho,

Nobuo Cho

Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd., Fujisawa, Kanagawa, Japan

Search for more papers by this author

Mikihiko Naito,

Corresponding Author

Mikihiko Naito

[email protected]

orcid.org/0000-0003-0451-1337

Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan

Correspondence

Mikihiko Naito, Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.

Tel: +81-3-3700-9428; Fax: +81-3-3707-6950;

E-mail: [email protected]

Search for more papers by this author

Nobumichi Ohoka,

Nobumichi Ohoka

Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan

Search for more papers by this author

Katsunori Nagai,

Katsunori Nagai

Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd., Fujisawa, Kanagawa, Japan

Search for more papers by this author

Norihito Shibata,

Norihito Shibata

Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan

Search for more papers by this author

Takayuki Hattori,

Takayuki Hattori

Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan

Search for more papers by this author

Hiroshi Nara,

Hiroshi Nara

Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd., Fujisawa, Kanagawa, Japan

Search for more papers by this author

Nobuo Cho,

Nobuo Cho

Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd., Fujisawa, Kanagawa, Japan

Search for more papers by this author

Mikihiko Naito,

Corresponding Author

Mikihiko Naito

[email protected]

orcid.org/0000-0003-0451-1337

Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan

Correspondence

Mikihiko Naito, Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.

Tel: +81-3-3700-9428; Fax: +81-3-3707-6950;

E-mail: [email protected]

Search for more papers by this author

First published: 13 February 2017

https://doi.org/10.1111/cas.13198

Citations: 33

Funding Information

Japan Society for the Promotion of Science (KAKENHI Grants 26860049 to N.O.; 16H05090 and 16K15121 to M.N.), Japan Agency for Medical Research and Development (AMED) (15ak0101029 h1402 and 16ak0101029j1403 to M.N.; 16cm0106124j0001 to N.O.), Ministry of Health and Labour Welfare (to M.N) and Takeda Science Foundation (to N.O.).

Share a link

Email
Wechat
Bluesky

Abstract

We previously developed a hybrid small molecule SNIPER (Specific and Nongenetic IAP-dependent Protein ERaser) against transforming acidic coiled-coil-3 (TACC3), SNIPER(TACC3), that induces proteasomal degradation of TACC3 protein. In this study, we found that SNIPER(TACC3) induces cytoplasmic vacuolization derived from endoplasmic reticulum (ER) and paraptosis-like cell death selectively in cancer cells. Mechanistic analysis suggests that accumulation of ubiquitylated protein aggregates that requires X-linked inhibitor of apoptosis protein (XIAP) induces ER stress, which results in ER-stress responses involving X-box binding protein-1 (XBP-1) and ER-derived vacuolization in cancer cells. Importantly, inhibition of proteasome enhanced the SNIPER(TACC3)-induced vacuolization, and the combination treatment of SNIPER(TACC3) and bortezomib exhibited a synergistic anticancer activity in several cancer cell lines. The induction of paraptosis-like cell death in cancer cells by SNIPER(TACC3) could be applied to treat cancer cells resistant to undergo apoptosis by overexpression of XIAP.

Protein knockdown is a recently developed technology to degrade target proteins by a class of chemical compounds such as SNIPERs (Specific and Nongenetic IAP-dependent Protein Erasers) and PROTACs (Proteolysis Targeting Chimeras).1 These compounds are chimeric molecules containing a ligand for a target protein of interest connected by a linker to another ligand for a ubiquitin ligase, which are designed to crosslink these proteins to induce polyubiquitylation and proteasomal degradation of the target proteins. With methyl-bestatin (MeBS) as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase, we have developed several SNIPER compounds targeting cellular retinoic acid-binding protein 2 (CRABP2),2, 3 estrogen receptor α (ERα),4-6 and spindle regulatory protein transforming acidic coiled-coil-3 (TACC3).7 The SNIPERs against CRABP2 and ERα induce cIAP1-mediated ubiquitylation and proteasomal degradation of the target proteins as intended.3, 6 However, SNIPER(TACC3) requires anaphase-promoting complex/cyclosome with CDH1 (APC/C^CDH1) ubiquitin ligase instead of cIAP1 to induce ubiquitylation and degradation of TACC3 protein.7

A spindle-regulatory protein TACC3 is one of the attractive targets for cancer therapy because TACC3 is aberrantly expressed in various human cancers and its depletion leads to mitotic or postmitotic cell cycle arrest and occasionally induce apoptosis of cancer cells.8-13 We have previously shown that SNIPER(TACC3) induces apoptosis selectively in cancer cells expressing a large amount of TACC3 protein as compared with normal cells.7 However, caspase activation was not extensively observed in the SNIPER(TACC3)-treated cancer cells, suggesting the involvement of different cell death mechanisms.

Cell death is classified into several types, such as apoptosis, necrosis (necroptosis), autophagy-associated death, mitotic catastrophe, paraptosis and oncosis.14 Paraptosis has been characterized by cytoplasmic vacuolization that associates with extensive swelling of endoplasmic reticulum (ER), and mitochondria in some cases, in the absence of typical apoptotic features such as formation of apoptotic bodies and nuclear fragmentation.15 Several reports have shown that paraptosis or paraptosis-like cell death (PLCD) is induced by overexpression of oncogenic genes,16, 17 mutation or deletion of genes related to ER function,18-20 and exposure to natural or synthetic compounds.21-26 Notably, paraptosis or PLCD have been frequently observed in a variety of cancer cells but not in normal cells, therefore induction of paraptosis could be an alternative approach to kill cancer cells that are resistant to undergo apoptosis.21, 22, 24, 26 In this study, we demonstrate that SNIPER(TACC3) induces cytoplasmic vacuolization and PLCD in cancer cells. We also showed that the SNIPER(TACC3) sensitizes cancer cells to bortezomib.

Materials and Methods

Chemical compounds

SNIPER(TACC3)-1 and -2 were synthesized as described previously.7 The chemical synthesis and physicochemical data on the other compounds are provided in the Doc. S1, Schemes S1 and S2.

Cell culture

Human osteosarcoma U2OS, human fibrosarcoma HT1080, and human fetal lung fibroblast TIG1, TIG3, MRC5, MRC9 were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS) and 100 μg/mL of kanamycin (Sigma, St. Louis, MO, USA). Human breast carcinoma MCF-7, human myeloid leukemia K562 and human Burkitt's lymphoma Raji cells were maintained in RPMI 1640 medium containing 10% FBS and 100 μg/mL of kanamycin. Human multiple myeloma RPMI-8226 and KMS-11 cells were obtained from Japanese Collection of Research Bioresources (JCRB, Osaka, Japan) Cell Bank (JCRB0034 and JCRB1179), and these cells were maintained in RPMI 1640 medium containing 10% FBS and 100 μg/mL of kanamycin.

siRNA Transfection

Cells were transiently transfected with a gene-specific short interfering RNA (siRNA) or a negative control siRNA (QIAGEN, Valencia, CA, USA) using lipofectamine RNAi MAX reagent (Life Technologies, Carlsbad, CA, USA). The siRNA sequence used in this study were:

UBE1 (5′-GCGCCAAAUGAAUCCACAU-3′);
XBP1-1 (5′-GGAAGAACCUGUAGAAGAU-3′);
XBP1-2 (5′-CCUCUCUGCUUGGUGUAAA-3′);
ATF4-1 (5′-GCCUAGGUCUCUUAGAUGA-3′);
ATF4-2 (5′-CCACGUUGGAUGACACUUG-3′);
CHOP (5′-GCAGCGCAUGAAGGAGAAA-3′);
cIAP1-1 (5′-UCUAGAGCAGUUGAAGACAUCUCUU-3′);
cIAP1-2 (5′-GCUGUAGCUUUAUUCAGAAUCUGGU-3′);
XIAP-1 (5′-ACACUGGCACGAGCAGGGUUUCUUU-3′);
XIAP-2 (5′-GAAGGAGAUACCGUGCGGUGCUUUA-3′).

Western blotting

Cells were lysed with SDS lysis buffer (0.1 M Tris–HCl at pH 8.0, 10% glycerol, 1% SDS) and immediately boiled for 10 min to obtain clear lysates. The protein concentration was measured by BCA method (Pierce, Rockford, IL, USA) and the lysates containing an equal amount of proteins were separated by SDS-PAGE, transferred to PVDF membranes (Millipore, Darmstadt, Germany) for western blot analysis using the appropriate antibodies. The immunoreactive proteins were visualized using the Immobilon Western chemiluminescent HRP substrate (Millipore) or Clarity Western ECL substrate (Bio-Rad, Hercules, CA, USA), and light emission was quantified with a LAS-3000 lumino-image analyzer (Fuji, Tokyo, Japan). The antibodies used in this study were: ATF4 (Cell Signaling Technology, 11815, Danvers, MA, USA), CHOP (Santa Cruz, Dallas, TX, USA; sc-793), cIAP1 (R&D Systems, Minneapolis, MN, USA; AF8181), β-actin (Sigma A5316), XIAP (Cell Signaling Technology, 2042), LC3 (Sigma; L7543, MBL, Nagoya, Japan; M115-3), XBP-1 (Santa Cruz, sc-7160; Cell signaling Technology, 12782), UBE1 (Cell Signaling Technology, 4890), Hsp90 (BD Biosciences, 610419, San Jose, CA, USA).

Immunostaining

Cells were fixed in 100% methanol on ice for 10 min, washed four times with PBS, and blocked in PBS containing 3% BSA, 0.1% Triton X-100 (PBS-TB) for 1 h at room temperature. Cells were incubated for 2 h with the indicated antibodies as the first antibodies, and for 1 h with Alexa Fluor 488-conjugated anti-rabbit or mouse IgG or Alexa Fluor 568-conjugated anti-rabbit or mouse IgG (Life Technologies) as the second antibodies with Hoechst 33342 (Life Technologies). Fluorescent images were obtained using a BZ-9000 (Keyence, Osaka, Japan). The antibodies used were: multi-ubiquitin (MBL, D058-3), ubiquitin, Lys48-Specific (Millipore; 05-1307), TACC3 (Cell Signaling, 8069), LAMP2 (BD Biosciences, 555803), PMP70 (Abcam, Cambridge, UK; ab85550), GM130 (Abcam, ab52649), COX IV (Cell Signaling, 4850).

Cell viability assay

Cell viability was determined using water-soluble tetrazolium WST-8 (4-[3-(2-methoxy-4-nitrophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) for the spectrophotometric assay according to the manufacturer's instructions (Dojindo, Tokyo, Japan). Cells treated with compounds were incubated with WST-8 reagent for 0.5 h at 37°C in a humidified atmosphere of 5% CO₂. The absorbance at 450 nm of the medium was measured using an EnVision Multilabel Plate Reader (PerkinElmer, Waltham, MA, USA).

Statistical analysis

A student's t-test was used to determine the significance of differences among the experimental groups. Values of P < 0.05 were considered significant.

Results

SNIPER(TACC3) induces cytoplasmic vacuolization in cancer cells

When human osteosarcoma U2OS cells were treated with SNIPER(TACC3)-1 and -2, the cells formed remarkable cytoplasmic vacuolization (Fig. 1a, b). SNIPER(TACC3)s contain two different ligands, MeBS for cIAP1 and KHS108 for TACC3, which are connected by linkers. Combination treatment with MeBS and KHS108 did not induce cytoplasmic vacuolization, indicating that linking the two ligands is critically needed for the induction of cytoplasmic vacuolization. To investigate which chemical structure of SNIPER(TACC3) is required for the vacuolization, we replaced the KHS108 moiety of SNIPER(TACC3) with benzoyl-amide or biotin, and the resulting compounds did not induce vacuole formation (Fig. 1b; compound 10 and 13). In addition, other SNIPERs targeting CRABP23 and ERα did not induce cytoplasmic vacuolization6 (Fig. S1). We further derivatized the SNIPER(TACC3) by replacing bestatin moiety to MV1, another IAP ligand, and this compound induced vacuolization as well as SNIPER(TACC3)-1 and -2 (Fig. 1b; compound 19). However, substitution of bestatin with fluorescein isothiocyanate (FITC) lost the ability to induce vacuolization (Fig. 1b; compound 17). Notably, the compounds with the activity to induce vacuolization caused cell death (Fig 1c). These results suggest that conjugating KHS108 to IAP ligands is required for the induction of vacuolization and cell death. Hereafter, we mainly used SNIPER(TACC3)-2 in the following experiments.

Details are in the caption following the image — **Figure 1**
Open in figure viewer PowerPoint

SNIPER(TACC3) induces cytoplasmic vacuolization in cancer cells. (a) Chemical structures of SNIPER(TACC3) and its analogs. (b) U2OS cells were treated with DMSO control, 30 μM SNIPER(TACC3)-1 and -2, mixture of MeBS and KHS108, compound 10, compound 13, compound 19 or compound 17 for 5 h. Phase-contrast images were obtained. *Scale Bars*: 20 μm. (c) U2OS cells were treated with 30 μM of the indicated compounds for 16 h and cell viability was measured by WST-8 cell proliferation assay. The graphs show the means ± SD of a representative experiment performed in triplicate; asterisks indicate P < 0.05 compared with DMSO control. (d) SNIPER(TACC3) induces cytoplasmic vacuolization in cancer cells but not normal cells. Cells were treated with 30 μM SNIPER(TACC3)-2 for 5 h. Phase-contrast images were observed by microscopy. *Scale Bars*: 20 μm.

SNIPER(TACC3)-2 also induced cytoplasmic vacuolization in human breast carcinoma MCF7 and human fibrosarcoma HT1080 cells, but not in normal human fibroblast TIG3, MRC5 and MRC9 cells (Fig 1d), suggesting that SNIPER(TACC3) induces cytoplasmic vacuolization selectively in cancer cells.

To investigate the origin of the vacuoles, we stained cells with a variety of organelle markers. The vacuole was not stained with LAMP2, PMP70, GM130 and COX IV, markers of lysosome, peroxisome, golgi apparatus and mitochondria, respectively, but clearly stained with ECFP-ER that has an ER localization signal (KDEL motif) (Fig. 2). These results strongly suggest that the vacuole is derived from ER.

SNIPER(TACC3) activates the X-linked inhibitor of apoptosis protein (XIAP)-mediated ubiquitylation and ER stress response selectively in cancer cells

To investigate the mechanism by which SNIPER(TACC3) induces cytoplasmic vacuolization, the effect of siRNA-mediated gene silencing was examined. The SNIPER(TACC3)-2-induced cytoplasmic vacuolization was prevented by silencing of ubiquitin-activating enzyme 1 (UBE1) (Fig. 3a), indicating that the ubiquitylation system is required for the vacuolization. To clarify the requirement of an IAP ubiquitin ligase for the vacuolization, we also silenced IAPs. IAP antagonists, such as MV1, are known to bind to cIAP1, cIAP2 and XIAP.27-29 Since cIAP2 is not expressed in U2OS cells, we focused on cIAP1 and XIAP. The silencing of XIAP, but not cIAP1, suppressed cytoplasmic vacuolization by SNIPER(TACC3)-2 (Figs 3b and S2). These results suggest that the XIAP-mediated ubiquitylation is required for the SNIPER(TACC3)-induced vacuole formation.

To examine if the ubiquitylation actually occurs in the SNIPER(TACC3)-treated cells, we immunostained the cells with antibodies against ubiquitin. Immunostaining with antibodies specific to multi-ubiquitin and K48-linked ubiquitin showed a punctate signal in the SNIPER(TACC3)-treated U2OS cells, suggesting that SNIPER(TACC3)-2 induces ubiquitylated protein aggregates in cytoplasm of U2OS cells (Fig. 4a). The ubiquitylated protein aggregates were not observed in normal fibroblasts TIG3 and MRC5 (Fig. 4b), indicating the selectivity to cancer cells. We then investigated the role of E1 and XIAP in the SNIPER(TACC3)-induced ubiquitylated protein aggregate formation. The silencing of UBE1 prevented the SNIPER(TACC3)-induced accumulation of ubiquitylated protein aggregates (Fig. 4c), which is consistent with the suppression of cytoplasmic vacuolization induced by SNIPER(TACC3) (Fig. 3a). In addition, XIAP silencing reduced the SNIPER(TACC3)-induced accumulation of ubiquitylated proteins (Fig. 4d), indicating that XIAP-mediated ubiquitylation takes place in the SNIPER(TACC3)-treated cells.

Since accumulation of ubiquitylated protein aggregates often causes ER stress in a variety of cell system,30, 31 we next examined ER stress responses in the SNIPER(TACC3)-treated cells. Consistent with the accumulation of ubiquitylated protein aggregates, SNIPER(TACC3)-2 induced the expression of activating transcription factor 4 (ATF4), C/EBP homologous protein (CHOP), and the spliced form of X-box binding protein-1 (XBP-1), mediators of ER-stress response, in U2OS cells, which were suppressed by E1 silencing (Fig. 3a). However, the ER stress responses were not observed in normal fibroblasts, TIG3 and MRC5 (Fig. 5a). To examine which ER-stress response pathway mediates the SNIPER(TACC3)-induced cytoplasmic vacuolization, we silenced ATF4, CHOP and XBP-1 in the cells. The silencing of XBP-1 repressed the SNIPER(TACC3)-2-induced vacuolization, while ATF4 and CHOP silencing did not (Fig. 5b), suggesting that XBP-1 plays an important role in mediating vacuole formation induced by SNIPER(TACC3)-2.

Cell death characterized by ER vacuolization accompanied by ER stress response and accumulation of ubiquitylated protein aggregates is known as paraptosis or PLCD,15, 16 and this type of cell death is often suppressed by a protein synthesis inhibitor and thiol antioxidants.16, 21-26 Consistent with these reports, the SNIPER(TACC3)-2-induced cytoplasmic vacuolization and cell death were also inhibited by co-treatment with cycloheximide (CHX) and thiol antioxidants, N-acetylcysteine (NAC) and N-(2-mercaptopropionyl)glycine (NMPG) (Fig. 5c,d). Necrosis (necroptosis) and oncosis also represent cell death with ER vacuolization, however, these types of cell death are not inhibited by CHX treatment.15, 16, 32, 33 Collectively, these results strongly suggest that SNIPER(TACC3) induces the accumulation of ubiquitylated protein aggregates mediated by XIAP, which causes ER stress and vacuole formation culminating in PLCD of cancer cells.

Combination of SNIPER(TACC3) and bortezomib

Bortezomib and MG132 induce ER stress by inhibiting proteasome, therefore, we next examined the combination of these drugs with SNIPER(TACC3) on the vacuole formation. As shown in Figure 6a, MG132 and bortezomib at 1 μM did not induce the vacuolization. However, they enlarged the size of vacuoles induced by 30 μM of SNIPER(TACC3)-2. They also induced vacuole formation when combined with 5, 10 and 20 μM of SNIPER(TACC3)-2 that scarcely induced vacuole formation by single treatments (Fig. 6a). These results suggest that proteasome inhibition enhances the SNIPER(TACC3)-induced vacuolization.

Since bortezomib is clinically used to treat multiple myelomas,34 we then evaluated the anticancer effects of SNIPER(TACC3)-2 in cancer cells including human multiple myeloma RPMI-8226 and KMS-11 cells, human Burkitt's lymphoma Raji cells and U2OS cells. The viability of these cancer cells were reduced by individual treatment of bortezomib and SNIPER(TACC3) in a dose-dependent manner (Fig. 6b,c). When these cancer cells were co-treated with suboptimal doses of bortezomib and SNIPER(TACC3), the viability was synergistically reduced (Fig. 6d). Thus, SNIPER(TACC3) sensitizes cancer cells to bortezomib.

Discussion

In our previous study, we developed SNIPER(TACC3)s that induces degradation of TACC3 protein via the ubiquitin-proteasome pathway.7 The SNIPER(TACC3) caused significant apoptosis in cancer cells expressing larger amount of TACC3 protein, however, caspase activation was not extensively observed.7 To understand how SNIPER(TACC3) induces cell death in cancer cells in more detail, we analyzed the SNIPER(TACC3)-treated cancer cells, and found that SNIPER(TACC3) also induces cytoplasmic vacuolization and PLCD selectively in cancer cells (Fig. 7). The SNIPER(TACC3)-induced degradation of TACC3 is important for induction of apoptosis in cancer cells.7 However, the downregulation of TACC3 is not likely to be involved in the induction of PLCD because the vacuolization was not blocked by siRNA-mediated knockdown of APC/C^CDH1-components that plays an important role in the TACC3 degradation by SNIPER(TACC3) (Fig. S3) and siRNA-mediated knockdown of TACC3 did not induce cytoplasmic vacuolization (Fig. S4).

The vacuolization and PLCD were induced by both bestatin-based and MV-1-based SNIPER(TACC3)s, but substitution of the IAP-ligands to FITC abolished the activity, suggesting that IAPs play a role in the SNIPER(TACC3)-induced vacuolization. In line with this, silencing of XIAP suppressed the SNIPER(TACC3)-induced accumulation of the ubiquitylated protein aggregates and cytoplasmic vacuolization, indicating an indispensable role of XIAP in this process. Thus, SNIPER(TACC3) induces XIAP-mediated ubiquitylation, which results in the accumulation of ubiquitylated protein aggregates. Since the ubiquitylated protein aggregates often cause cytoplasmic vacuolization,21, 22, 35-37 the SNIPER(TACC3)-induced accumulation of ubiquitylated aggregates would results in the vacuolization as well. At present, the ubiquitylated proteins included in the aggregates were not clear. TACC3 was not found in the aggregates (data not shown) probably because most of the TACC3 protein is degraded in the cells.

Although the ubiquitylated proteins are not identified, the protein aggregates accumulated in the SNIPER(TACC3)-treated cells would cause ER-stress. Substantial and prolonged accumulation of misfolded proteins in the ER would bring about extensive ER swelling. XBP-1 was reported to induce ER expansion and ER biogenesis.38, 39 Consistent with these reports, the vacuoles induced by SNIPER(TACC3) are derived from ER, and the vacuolization requires expression of XBP-1. This evidence suggests that the suppression of SNIPER(TACC3)-induced vacuolization by CHX (Fig. 5c) could be attributed to the inhibition of XBP-1 expression (Fig. S5).

The SNIPER(TACC3)-induced cytoplasmic vacuolization and PLCD were observed in cancer cells but not in normal fibroblasts. Since cancer cells accumulate mutations in their genome, they produce more amounts of abnormal mutant proteins than normal cells, and therefore, cancer cells are constantly under an ER-stressed condition.40 In addition, new protein synthesis and thiol homeostasis are more essential for rapidly growing cancer cells than quiescent normal cells.21, 22, 41 This evidence could explain, at least in part, why SNIPER(TACC3) showed selectivity to cancer cells. In addition, the expression level of XIAP might be involved in the selectivity to cancer cells, because XIAP is overexpressed in a variety of cancer cells.42, 43

Bortezomib enhanced the SNIPER(TACC3)-induced vacuolization, and the combination treatment of bortezomib and SNIPER(TACC3) exhibited a synergistic anticancer activity against several cancer cell lines. Since SNIPER(TACC3) impedes ER-associated protein degradation (ERAD) system, a target of proteasome inhibitors, and induces ER stress responses, the susceptibility of cancer cells to bortezomib could be enhanced by SNIPER(TACC3). Combination of these would be effective to treat a variety of cancers represented by multiple myelomas, in which the ER is expanded to accommodate the synthesis of secretory immunoglobulin.44 Meanwhile, the SNIPER(TACC3)-induced PLCD was mediated by XIAP as described above, which is involved in the resistance to cancer therapy by inhibiting apoptosis.42, 43 Therefore, the induction of PLCD by SNIPER(TACC3) might be applied to treat cancers resistant to apoptosis by overexpression of XIAP.

Acknowledgments

The authors appreciate Dr. K. Okuhira for helpful discussions. We thank Dr. M. Tada for kindly providing CFP-ER plasmid. This work was supported in part by grants from Japan Society for the Promotion of Science (KAKENHI Grants 26860049 to N.O.; 16H05090 and 16K15121 to M.N.), Japan Agency for Medical Research and Development (AMED) (15ak0101029 h1402 and 16ak0101029j1403 to M.N.; 16cm0106124j0001 to N.O.), Ministry of Health and Labour Welfare (to M.N) and Takeda Science Foundation (to N.O.).

Disclosure Statement

K. Nagai, H. Nara and N. Cho are employees of Takeda Pharmaceutical Co., Ltd. M. Naito received a research fund from Takeda Pharmaceutical Company (Osaka, Japan). The other authors declare no conflict of interest.

Abbreviations

APC/C^CDH1: anaphase-promoting complex/cyclosome with CDH1
ATF4: activating transcription factor 4
CHOP: C/EBP homologous protein
CHX: cycloheximide
cIAP1: cellular inhibitor of apoptosis protein 1
CRABP2: cellular retinoic acid-binding protein 2
ERAD: ER-associated protein degradation
ER: endoplasmic reticulum
ERα: estrogen receptor α
FITC: fluorescein isothiocyanate
MeBS: methyl-bestatin
NAC: N-acetylcysteine
NMPG: N-(2-mercaptopropionyl)glycine
PLCD: paraptosis-like cell death
PROTAC: Proteolysis Targeting Chimera
SNIPER: Specific and Nongenetic IAP-dependent Protein ERaser
TACC3: transforming acidic coiled-coil-3
XBP-1: X-box binding protein-1
XIAP: X-linked inhibitor of apoptosis protein

Supporting Information

Filename	Description
cas13198-sup-0001-FigS1.jpgimage/jpg, 682.1 KB	Fig. S1. SNIPER (CRABP2) does not induce cytoplasmic vacuolization.
cas13198-sup-0002-FigS2.jpgimage/jpg, 803.5 KB	Fig. S2. Phase-contrast images of XIAP- and cIAP1-silenced cells treated without SNIPER(TACC3), corresponding to Fig. 3b.
cas13198-sup-0003-FigS3.jpgimage/jpg, 876.5 KB	Fig. S3. APC3 and CDH1 silencing represses the degradation of TACC3, but not the vacuolization, induced by SNIPER(TACC3).
cas13198-sup-0004-FigS4.jpgimage/jpg, 740.2 KB	Fig. S4. TACC3 silencing does not induce cytoplasmic vacuolization.
cas13198-sup-0005-FigS5.jpgimage/jpg, 712.6 KB	Fig. S5. CHX, but not NAC and NMPG, inhibits the SNIPER(TACC3)-induced XBP1 expression.
cas13198-sup-0006-SupInfo.docxWord document, 37.9 KB	Doc. S1. The chemical synthesis and physicochemical data.
cas13198-sup-0007-SchemeS1.docxWord document, 99.6 KB	Scheme S1. Synthesis of the compounds 10 and 13.
cas13198-sup-0008-SchemeS2.docxWord document, 87.3 KB	Scheme S2. Synthesis of the compounds 17 and 19.

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

References

1Ohoka N, Shibata N, Hattori T, Naito M. Protein knockdown technology: application of ubiquitin ligase to cancer therapy. Curr Cancer Drug Targets 2016; 16: 136–46.
10.2174/1568009616666151112122502
CAS PubMed Web of Science® Google Scholar
2Itoh Y, Ishikawa M, Naito M, Hashimoto Y. Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. J Am Chem Soc 2010; 132: 5820–6.
10.1021/ja100691p
CAS PubMed Web of Science® Google Scholar
3Okuhira K, Ohoka N, Sai K et al. Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein. FEBS Lett 2011; 585: 1147–52.
10.1016/j.febslet.2011.03.019
CAS PubMed Web of Science® Google Scholar
4Demizu Y, Okuhira K, Motoi H et al. Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy. Bioorg Med Chem Lett 2012; 22: 1793–6.
10.1016/j.bmcl.2011.11.086
CAS PubMed Web of Science® Google Scholar
5Okuhira K, Demizu Y, Hattori T et al. Molecular design, synthesis, and evaluation of SNIPER(ER) that induces proteasomal degradation of ERalpha. Methods Mol Biol 2016; 1366: 549–60.
10.1007/978-1-4939-3127-9_42
CAS PubMed Web of Science® Google Scholar
6Okuhira K, Demizu Y, Hattori T et al. Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells. Cancer Sci 2013; 104: 1492–8.
10.1111/cas.12272
CAS PubMed Web of Science® Google Scholar
7Ohoka N, Nagai K, Hattori T et al. Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway. Cell Death Dis 2014; 5: e1513.
10.1038/cddis.2014.471
CAS PubMed Web of Science® Google Scholar
8Ma XJ, Salunga R, Tuggle JT et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003; 100: 5974–9.
10.1073/pnas.0931261100
CAS PubMed Web of Science® Google Scholar
9Ulisse S, Baldini E, Toller M et al. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocr Relat Cancer 2007; 14: 827–37.
10.1677/ERC-07-0053
CAS PubMed Web of Science® Google Scholar
10Peters DG, Kudla DM, Deloia JA et al. Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. Cancer Epidemiol Biomarkers Prev 2005; 14: 1717–23.
10.1158/1055-9965.EPI-04-0704
CAS PubMed Web of Science® Google Scholar
11Kiemeney LA, Sulem P, Besenbacher S et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010; 42: 415–19.
10.1038/ng.558
CAS PubMed Web of Science® Google Scholar
12Yao R, Natsume Y, Saiki Y et al. Disruption of Tacc3 function leads to in vivo tumor regression. Oncogene 2012; 31: 135–48.
10.1038/onc.2011.235
CAS PubMed Web of Science® Google Scholar
13Yao R, Kondoh Y, Natsume Y et al. A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells. Oncogene 2014; 33: 4242–52.
10.1038/onc.2013.382
CAS PubMed Web of Science® Google Scholar
14Bredesen DE, Rao RV, Mehlen P. Cell death in the nervous system. Nature 2006; 443: 796–802.
10.1038/nature05293
CAS PubMed Web of Science® Google Scholar
15Shubin AV, Demidyuk IV, Komissarov AA, Rafieva LM, Kostrov SV. Cytoplasmic vacuolization in cell death and survival. Oncotarget 2016; 7: 55863–89.
10.18632/oncotarget.10150
PubMed Web of Science® Google Scholar
16Sperandio S, de Belle I, Bredesen DE. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA 2000; 97: 14376–81.
10.1073/pnas.97.26.14376
CAS PubMed Web of Science® Google Scholar
17Denoyelle C, Abou-Rjaily G, Bezrookove V et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 2006; 8: 1053–63.
10.1038/ncb1471
CAS PubMed Web of Science® Google Scholar
18Kobayashi T, Tanaka K, Inoue K, Kakizuka A. Functional ATPase activity of p97/valosin-containing protein (VCP) is required for the quality control of endoplasmic reticulum in neuronally differentiated mammalian PC12 cells. J Biol Chem 2002; 277: 47358–65.
10.1074/jbc.M207783200
CAS PubMed Web of Science® Google Scholar
19Chatellard-Causse C, Blot B, Cristina N, Torch S, Missotten M, Sadoul R. Alix (ALG-2-interacting protein X), a protein involved in apoptosis, binds to endophilins and induces cytoplasmic vacuolization. J Biol Chem 2002; 277: 29108–15.
10.1074/jbc.M204019200
CAS PubMed Web of Science® Google Scholar
20Munoz JP, Ivanova S, Sanchez-Wandelmer J et al. Mfn2 modulates the UPR and mitochondrial function via repression of PERK. EMBO J 2013; 32: 2348–61.
10.1038/emboj.2013.168
CAS PubMed Web of Science® Google Scholar
21Kar R, Singha PK, Venkatachalam MA, Saikumar P. A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells. Oncogene 2009; 28: 2556–68.
10.1038/onc.2009.118
CAS PubMed Web of Science® Google Scholar
22Singha PK, Pandeswara S, Venkatachalam MA, Saikumar P. Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death. Cell Death Dis 2013; 4: e457.
10.1038/cddis.2012.192
CAS PubMed Web of Science® Google Scholar
23Wang WB, Feng LX, Yue QX et al. Paraptosis accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90. J Cell Physiol 2012; 227: 2196–206.
10.1002/jcp.22956
CAS PubMed Web of Science® Google Scholar
24Wasik AM, Almestrand S, Wang X et al. WIN55,212-2 induces cytoplasmic vacuolation in apoptosis-resistant MCL cells. Cell Death Dis 2011; 2: e225.
10.1038/cddis.2011.106
CAS PubMed Web of Science® Google Scholar
25Tardito S, Isella C, Medico E et al. The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem 2009; 284: 24306–19.
10.1074/jbc.M109.026583
CAS PubMed Web of Science® Google Scholar
26Yoon MJ, Kang YJ, Lee JA et al. Stronger proteasomal inhibition and higher CHOP induction are responsible for more effective induction of paraptosis by dimethoxycurcumin than curcumin. Cell Death Dis 2014; 5: e1112.
10.1038/cddis.2014.85
CAS PubMed Web of Science® Google Scholar
27Varfolomeev E, Blankenship JW, Wayson SM et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669–81.
10.1016/j.cell.2007.10.030
CAS PubMed Web of Science® Google Scholar
28Vince JE, Wong WW, Khan N et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682–93.
10.1016/j.cell.2007.10.037
CAS PubMed Web of Science® Google Scholar
29Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004; 305: 1471–4.
10.1126/science.1098231
CAS PubMed Web of Science® Google Scholar
30Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001; 292: 1552–5.
10.1126/science.292.5521.1552
CAS PubMed Web of Science® Google Scholar
31Rao RV, Bredesen DE. Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr Opin Cell Biol 2004; 16: 653–62.
10.1016/j.ceb.2004.09.012
CAS PubMed Web of Science® Google Scholar
32Hallock S, Tang SC, Buja LM, Trump BF, Liepins A, Weerasinghe P. Aurintricarboxylic acid inhibits protein synthesis independent, sanguinarine-induced apoptosis and oncosis. Toxicol Pathol 2007; 35: 300–9.
10.1080/01926230701194211
CAS PubMed Web of Science® Google Scholar
33Suarez Y, Gonzalez L, Cuadrado A, Berciano M, Lafarga M, Munoz A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2003; 2: 863–72.
CAS PubMed Web of Science® Google Scholar
34Pitcher DS, de Mattos-Shipley K, Tzortzis K, Auner HW, Karadimitris A, Kleijnen MF. Bortezomib amplifies effect on intracellular proteasomes by changing proteasome structure. EBioMedicine 2015; 2: 642–8.
10.1016/j.ebiom.2015.05.016
PubMed Web of Science® Google Scholar
35Ju JS, Fuentealba RA, Miller SE et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol 2009; 187: 875–88.
10.1083/jcb.200908115
CAS PubMed Web of Science® Google Scholar
36Wojcik C, Yano M, DeMartino GN. RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. J Cell Sci 2004; 117: 281–92.
10.1242/jcs.00841
CAS PubMed Web of Science® Google Scholar
37Hirabayashi M, Inoue K, Tanaka K et al. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ 2001; 8: 977–84.
10.1038/sj.cdd.4400907
CAS PubMed Web of Science® Google Scholar
38Shaffer AL, Shapiro-Shelef M, Iwakoshi NN et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004; 21: 81–93.
10.1016/j.immuni.2004.06.010
CAS PubMed Web of Science® Google Scholar
39Sriburi R, Bommiasamy H, Buldak GL et al. Coordinate regulation of phospholipid biosynthesis and secretory pathway gene expression in XBP-1(S)-induced endoplasmic reticulum biogenesis. J Biol Chem 2007; 282: 7024–34.
10.1074/jbc.M609490200
CAS PubMed Web of Science® Google Scholar
40Yadav RK, Chae SW, Kim HR, Chae HJ. Endoplasmic reticulum stress and cancer. J Cancer Prev 2014; 19: 75–88.
10.15430/JCP.2014.19.2.75
PubMed Google Scholar
41Traverso N, Ricciarelli R, Nitti M et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev 2013; 2013: 972913.
10.1155/2013/972913
CAS PubMed Web of Science® Google Scholar
42Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012; 11: 109–24.
10.1038/nrd3627
CAS PubMed Web of Science® Google Scholar
43Pedersen J, LaCasse EC, Seidelin JB, Coskun M, Nielsen OH. Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends Mol Med 2014; 20: 652–65.
10.1016/j.molmed.2014.09.006
CAS PubMed Web of Science® Google Scholar
44Leung-Hagesteijn C, Erdmann N, Cheung G et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013; 24: 289–304.
10.1016/j.ccr.2013.08.009
CAS PubMed Web of Science® Google Scholar
45Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981; 35: 269–335.
10.1016/S0065-230X(08)60912-4
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume108, Issue5

May 2017

Pages 1032-1041

SNIPER(TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib

Abstract